Abstract
Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ("precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+ KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+ KIT screening were required for targeted drug selection, with the remaining 52% (22/42) prescribed drugs independent of the screening results for various reasons. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.
Original language | English |
---|---|
Article number | 1551 |
Journal | F1000Research |
Volume | 5 |
DOIs | |
Publication status | Published - 2016 |
Keywords
- Bevacizumab
- Dabrafenib erlotinib
- Malignant melanoma
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Oncology
- Precision medicine
- Targeted pharmacotherapy